Article

Collagen crosslinking helps with stabilizing progressive hyperopia post-RK

Collagen crosslinking with riboflavin (C3-R) was used to treat six eyes with progressive hyperopia after RK that had experienced further progression after intervention using laser vision correction. Retrospective analyses based on a mean follow-up of 215 days after the C3-R procedure suggests keratometric stabilization.

Beverly Hills, CA–Collagen crosslinking with riboflavin (C3-R) is showing promise as a method for arresting progressive hyperopia after RK and laser ablation, said Brian S. Boxer Wachler, MD.

Mean follow-up for the six eyes was 215 days (range, 30 to 450 days). Outcomes analyzed included change in uncorrected visual acuity, best-corrected visual acuity, sphere, cylinder, spherical equivalent, keratometry (steep, flat, average), and endothelial cell count. None of those parameters changed significantly. Looking at individual values, no eye experienced more than 1 D of change in sphere or refractive cylinder or significant worsening of corneal topography, and a few exhibited keratometric steepening.

"However, based on these preliminary results, we are hopeful that stabilization is occurring and that this might be a nice treatment to offer patients who are suffering from progressive hyperopia after RK," he added.

Explaining the rationale, Dr. Boxer Wachler said post-RK corneas are often- although not always-unstable and that C3-R strengthens the cornea by causing fibril thickening and crosslinking.

"Pioneering work from Theo Seiler, MD, PhD, established that this technique could safely stabilize keratoconus, essentially by increasing biomechanical stiffness and making the cornea stronger," Dr. Boxer Wachler said.

"Its efficacy and safety as measured by lack of adverse changes in corneal and lens transparency, IOP, and endothelial cell count has subsequently been confirmed by other investigators," he said.

"We've been interested in evaluating the crosslinking procedure for stabilizing keratometry in corneas with a variety of pathologies, including progressive hyperopia post-RK. These latter eyes often go on to treatment with hyperopic LASIK or PRK," he added. "However, if the cornea is inherently unstable, the improvement gained with those procedures is likely to be only a temporary effect."

The treatment protocol was similar to that described by Wollensak and Seiler in their original 2003 paper in the American Journal of Ophthalmology with the exception that Dr. Boxer Wachler does not remove the epithelium. The central 7 mm of the cornea is exposed to 370-nm ultraviolet-A irradiation (5.4 J/cm2 ) for 30 minutes with application of the photosensitizing solution containing 0.1% riboflavin-5-phosphate and dextran prior to and every 3 minutes during the light treat- ment, he said.

The five patients analyzed had a mean age of 51 years and comprised two males and three females.

Individual results showed that sphere increased slightly in three eyes and decreased slightly in the other three; mean preoperative sphere was 2.04 D and was unchanged postoperatively.

Cylinder was unchanged in two eyes, increased slightly in two eyes, and decreased slightly in two eyes. Mean preoperative sphere was –1.88 D and decreased by an average of 0.04 D.

The average K value was 40.01 D preoperatively and was essentially unchanged at 39.98 D at the last postoperative visit, he said.

"The changes in keratometry observed in some of these patients are consistent with the idea that if RK weakens and flattens the cornea, this procedure may be tightening the incisions and thereby causing corneal steepening," Dr. Boxer Wachler said.

Mean endothelial cell count increased from 2,447 cells/mm2 to 2,711 cells/mm2 .

"The latter change likely reflects variability of the measurement rather than any effect of the procedure," Dr. Boxer Wachler said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.